Literature DB >> 25886696

Wnt11 gene therapy with adeno-associated virus 9 improves the survival of mice with myocarditis induced by coxsackievirus B3 through the suppression of the inflammatory reaction.

Yutaka Aoyama1, Koichi Kobayashi2, Yoshihiro Morishita1, Kengo Maeda1, Toyoaki Murohara1.   

Abstract

The wnt signaling pathway plays important roles in development and in many diseases. Recently several reports suggest that non-canonical Wnt proteins contribute to the inflammatory response in adult animals. However, the effects of Wnt proteins on virus-induced myocarditis have not been explored. Here, we investigated the effect of Wnt11 protein in a model of myocarditis induced by coxsackievirus B3 (CVB3) using recombinant adeno-associated virus 9 (rAAV9). The effect of Wnt11 gene therapy on a CVB3-induced myocarditis model was examined using male BALB/c mice. Mice received a single intravenous injection of either rAAV9-Wnt11 or rAAV9-LacZ 2 weeks before intraperitoneal administration of CVB3. Intravenous injection of the rAAV9 vector resulted in efficient, durable, and relatively cardiac-specific transgene expression. Survival was significantly greater among rAAV9-Wnt11 treated mice than among mice treated with rAAV9-LacZ (87.5% vs. 54.1%, P < 0.05). Wnt11 expression also reduced the infiltration of inflammatory cells, necrosis of the myocardium, and suppressed the mRNA expression of inflammatory cytokines. This is the first report to show that Wnt11 expression improves the survival of mice with CVB3-induced myocarditis. AAV9-mediated Wnt11 gene therapy produces beneficial effects on cardiac function and increases the survival of mice with CVB3-induced myocarditis through the suppression of both infiltration of inflammatory cells and gene expression of inflammatory cytokines.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Adeno-associated virus 9; Inflammation; Viral myocarditis; Wnt11

Mesh:

Substances:

Year:  2015        PMID: 25886696     DOI: 10.1016/j.yjmcc.2015.04.009

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  6 in total

Review 1.  Wnt Signaling in Heart Development and Regeneration.

Authors:  Dongliang Li; Jianjian Sun; Tao P Zhong
Journal:  Curr Cardiol Rep       Date:  2022-08-04       Impact factor: 3.955

2.  MicroRNA-21 Lowers Blood Pressure in Spontaneous Hypertensive Rats by Upregulating Mitochondrial Translation.

Authors:  Huaping Li; Xiaorong Zhang; Feng Wang; Ling Zhou; Zhongwei Yin; Jiahui Fan; Xiang Nie; Peihua Wang; Xiang-Dong Fu; Chen Chen; Dao Wen Wang
Journal:  Circulation       Date:  2016-08-19       Impact factor: 29.690

3.  MicroRNA-30c suppresses the pro-fibrogenic effects of cardiac fibroblasts induced by TGF-β1 and prevents atrial fibrosis by targeting TGFβRII.

Authors:  Juan Xu; Haiqing Wu; Songwen Chen; Baozhen Qi; Genqing Zhou; Lidong Cai; Liqun Zhao; Yong Wei; Shaowen Liu
Journal:  J Cell Mol Med       Date:  2018-03-13       Impact factor: 5.310

4.  Differential expression of circulating miRNAs as a novel tool to assess BAG3-associated familial dilated cardiomyopathy.

Authors:  Carlos Zaragoza; Marta Saura; Ignacio Hernández; Rafael Ramirez-Carracedo; Francisco García-García; Jose L Zamorano; Alipio Mangas; Rocio Toro
Journal:  Biosci Rep       Date:  2019-03-15       Impact factor: 3.840

5.  Crucial Role of miR-433 in Regulating Cardiac Fibrosis.

Authors:  Lichan Tao; Yihua Bei; Ping Chen; Zhiyong Lei; Siyi Fu; Haifeng Zhang; Jiahong Xu; Lin Che; Xiongwen Chen; Joost Pg Sluijter; Saumya Das; Dragos Cretoiu; Bin Xu; Jiuchang Zhong; Junjie Xiao; Xinli Li
Journal:  Theranostics       Date:  2016-09-10       Impact factor: 11.556

6.  Wnt11 Gene Therapy with Adeno-associated Virus 9 Improves Recovery from Myocardial Infarction by Modulating the Inflammatory Response.

Authors:  Yoshihiro Morishita; Koichi Kobayashi; Ekaterina Klyachko; Kentaro Jujo; Kengo Maeda; Douglas W Losordo; Toyoaki Murohara
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.